Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Articles

Italian study finds most MS patients start biosimilars unaware, exposing education gaps and highlighting MS nurses as key to boosting trust and uptake.

Low Biosimilar Awareness in MS Patients Points to Critical Gap in Nurse-Led Education

New EULAR guidelines speed RA treatment switches as rheumatoid arthritis biosimilars and cost savings push earlier biologics use.

Biosimilar Expansion, Lower Costs Drive Shift in RA Treatment Guidelines

Dr. Cyrus Karkaria is President of Lupin's Biotechnology Businesses, leading the company's global biosimilars portfolio with over 30 years of biologic drug development experience at organizations including Biogen, CuraGen, and Celldex Therapeutics. He holds a post-doctorate from Harvard Medical School and a PhD. from the University of Maryland.

The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.

FDA Approves Ranibizumab-hkdz as First Interchangeable, Available in Both Vials and Prefilled Syringes

Evidence shows biosimilars switching in ankylosing spondylitis maintains disease control with biologics, cuts costs, and highlights nocebo risks.

Biosimilar Switching Maintained Disease Control in People With Ankylosing Spondylitis

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

The Center for Biosimilars - Biosimilars, Health Economics & Insights

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Continuing Medical Education

AMCP Annual 2026

Asembia 2026

Tuesday, December 16, 2025 | 7:00 – 8:30 PM ET

Navigating Outpatient Bispecific Antibody Administration in Lymphoma: Practical Solutions for Community Oncology Practices

Free CE Activities

EVENTS

ACTIVITIES